Response letter regarding the letter to the editors by Brown et al.

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 7, 2016, Pages 1943-1946

  Taylor, Sylvia ^a   Ryser, Martin ^a   Mihalyi, Attila ^a   van Effelterre, Thierry ^a  

^a GSK   (Belgium)

Author keywords

Cervarix ; cervical cancer; cross protection; HPV; universal mass vaccination

Indexed keywords

WART VIRUS VACCINE;

ANTIBODY TITER; CROSS PROTECTION; DRUG EFFICACY; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; IMMUNE RESPONSE; IMMUNOGENICITY; INCIDENCE; LETTER; PAPILLOMAVIRUS INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRUS LIKE AGENT; WART VIRUS; IMMUNOLOGY; UTERINE CERVIX TUMOR;

HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 84966694876     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2016.1151598     Document Type: Letter

References (21)

1. T.Malagón, M.Drolet, M.C.Boily, E.L.Franco, M.Jit, J.Brisson, M.Brisson. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012 Oct; 12(10):781-9; PMID:22920953; http://dx.doi.org/10.1016/S1473-3099(12)70187-1. Epub 2012 Aug 22.
2. GSK Clinical Study Register. Study of the efficacy of candidate HPV 16/18 VLP vaccine in the prevention of HPV-16 and/or HPV-18 cervical infection in adolescent & young adult women in North America and Brazil vaccinated in primary study 580299/001. Available from: http://www.gsk-clinicalstudyregister.com/study/580299/007?study_ids=580299/007#ps. Updated 2011 Oct 27; accessed 2015 Sep 1. GSK Study ID 580299/007.
3. GSK Clinical Study Register. Follow-up study to evaluate the long-term efficacy of a HPV vaccine (580299) in healthy young adult women in Brazil. In: GSK Clinical Study Register [Internet]. Available from: http://www.gsk-clinicalstudyregister.com/study/109616%20%28Y7%29#rs. Updated 2014 Nov 20; accessed 2015 Sep 1. GSK Clinical Study Register Identifier: 109616 (Y7).
4. S.R.Skinner, D.Apter, N.De Carvalho, D.M.Harper, R.Konno, J.Paavonen, B.Romanowski, C.Roteli-Martins, N.Burlet, A.Mihalyi and F.StruyfFrank. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases. Exp Rev Vacc 15(3):367-387. http://dx.doi.org/10.1586/14760584.2016.1124763. Epub 2016 Feb 22.
5. A.R.Kreimer, F.Struyf, M.R.Del Rosario-Raymundo, A.Hildesheim, S.R.Skinner, S.Wacholder, S.M.Garland, R.Herrero, M.P.David, C.M.Wheeler et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol 2015 Jul; 16(7):775-86; PMID:26071347; http://dx.doi.org/10.1016/S1470-2045(15)00047-9; Epub 2015 Jun 9
6. Moscicki A-B, Harper D, Naud P, Wheeler C, Blatter M, De Carvalho N, Ferris D, Roteli-Martins C, Teixeira J, Tyring S et al. HPV-16/18 AS04-adjuvanted vaccine: sustained immunogenicity against HPV-31 and HPV-45 non-vaccine oncogenic types up to 9.4 years follow-up [Abstract HPV15-0620]. In Proceedings of the International Papillomavirus Society - 30th International Papillomavirus Conference. Lisbon, Portugal: 2015 Sep 17-21.
7. GSK Clinical Study Register. A study to evaluate safety, immunogenicity and efficacy of GSK Biologicals HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a three-dose schedule (0, 1, 6 month) in healthy adult female subjects aged 26 years and above. Available from: http://www.gsk-clinicalstudyregister.com/study/104820#rs. Updated 2015 Dec 7; accessed 2015 Dec 7. GSK Clinical Study Register Identifier: 104820.
8. S.R.Skinner, A.Szarewski, B.Romanowski, S.M.Garland, E.Lazcano-Ponce, J.Salmerón, M.R.Del Rosario-Raymundo, R.H.Verheijen, S.C.Quek, D.P.da Silva, et al. Efficacy, safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in women over 25 years: 4-year interim follow-up of the double-blind, randomised VIVIANE study. Lancet 2014 Dec 20; 384(9961):2213-27; http://dx.doi.org/10.1016/S0140-6736(14)60920-X. Epub 2014 Sep 1
9. R.L.Cameron, K.Kavanagh, J.Pan, J.Love, K.Cuschieri, C.Robertson, S.Ahmed, T.Palmer, K.G.Pollock. Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009-2013. Emerg Infect Dis 2016 Jan; 22(1):56-64; PMID:26692336; http://dx.doi.org/10.3201/eid2201.150736
10. E.A.Joura, A.R.Giuliano, O.E.Iversen, C.Bouchard, C.Mao, J.Mehlsen, E.D.MoreiraJr, Y.Ngan, L.K.Petersen, E.Lazcano-Ponce, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015 Feb 19;372(8):711-23; PMID: 25693011; http://dx.doi.org/10.1056/NEJMoa1405044
11. S.Di Mario, V.Basevi, P.L.Lopalco, S.Balduzzi, R.D'Amico, N.Magrini. Are the two human papillomavirus vaccines really similar? A systematic review of available evidence: efficacy of the two vaccines against HPV. J Immunol Res 2015; 2015:435141. doi: 10.1155/2015/435141. Epub 2015 Aug 25. Review. PubMed PMID: 26380321; PubMed Central PMCID: PMC4562171.
12. Vaccines and Related Biological Products Advisory Committee (VRBPAC). Cervarix human papillomavirus bivalent (types 16 and 18): briefing document [2009 Sep 9]; p64. In: US Food and Drug Administration [Internet]. Available from: http://www.fda.gov/downloads/Adviso..uctsAdvisoryCommittee/UCM181371.pdf.
13. M.Lehtinen, J.Paavonen, C.M.Wheeler, U.Jaisamrarn, S.M.Garland, X.Castellsagué, S.R.Skinner, D.Apter, P.Naud, J.Salmerón, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012 Jan; 13(1):89-99; Epub 2011 Nov 8. Erratum in: Lancet Oncol 2012 Jan;13(1):e1. PMID: 22075171; http://dx.doi.org/10.1016/S1470-2045(11)70286-8
14. K.A.Lang Kuhs, C.Porras, J.T.Schiller, A.C.Rodriguez, M.Schiffman, P.Gonzalez, S.Wacholder, A.Ghosh, Y.Li, D.R.Lowy, et al. Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. Am J Epidemiol 2014 Sep 15; 180(6):599-607; Epub 2014 Aug 19. PMID: 25139208; PubMed Central PMCID: PMC4157699; http://dx.doi.org/10.1093/aje/kwu168
15. R.Konno, H.Yoshikawa, M.Okutani, W.Quint, P.V Suryakiran, L.Lin, F.Struyf. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Hum Vaccin Immunother 2014; 10(7):1781-94; PubMed Central PMCID: PMC4186043; PMID:25424783; http://dx.doi.org/10.4161/hv.28712
16. GlaxoSmithKline Vaccine HPV-007 Study Group, B.Romanowski, P.C.de Borba, P.S.Naud, C.M.Roteli-Martins, N.S.De Carvalho, J.C.Teixeira, F.Aoki, B.Ramjattan, R.M.Shier, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009 Dec 12; 374(9706):1975-85; PMID: 19962185; http://dx.doi.org/10.1016/S0140-6736(09)61567-1
17. N.Muñoz, S.K.Kjaer, K.Sigurdsson, O.E.Iversen, M.Hernandez-Avila, C.M.Wheeler, G.Perez, D.R.Brown, L.A.Koutsky, E.H.Tay, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010 Mar 3; 102(5):325-39; PMID: 20139221; http://dx.doi.org/10.1093/jnci/djp534. Epub 2010 Feb 5.
18. Giuliano AR, Joura E, Iversen OE, Bautista O, Chen J, Moeller E, Ritter M, Luxembourg A. Efficacy of a novel 9-valent HPV L1 vaccine against disease irrespective of HPV type. In Proceedings of International Papillomavirus Society - 29th International Papillomavirus Conference: pg. 252 [Abstract PH.PD04.05]. Seattle, WA: 2014 Aug 21–25.
19. E.A.Joura, K.A.Ault, F.X.Bosch, D.Brown, J.Cuzick, D.Ferris, S.M.Garland, A.R.Giuliano, M.Hernandez-Avila, W.Huh, et al. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol Biomarkers Prev 2014 Oct;23(10):1997-2008; PMID: 25274978; http://dx.doi.org/10.1158/1055-9965.EPI-14-0410
20. L.A.Pinto, R.Viscidi, C.D.Harro, T.J.Kemp, A.J.García-Piñeres, M.Trivett, F.Demuth, D.R.Lowy, J.T.Schiller, J.A.Berzofsky, et al. Cellular immune responses to HPV-18, −31, and −53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. Virology 2006 Sep 30; 353(2):451-62. Epub 2006 Jul 24; http://dx.doi.org/10.1016/j.virol.2006.06.021
21. M.Boxus, L.Lockman, M.Fochesato, C.Lorin, F.Thomas, S.L.Giannini. Antibody avidity measurements in recipients of Cervarix vaccine following a two-dose schedule or a three-dose schedule. Vaccine 2014 May 30; 32(26):3232-6; Epub 2014 Apr 13; http://dx.doi.org/10.1016/j.vaccine.2014.04.005